4.3 Article

Grey-matter sodium concentration as an individual marker of multiple sclerosis severity

Journal

MULTIPLE SCLEROSIS JOURNAL
Volume 28, Issue 12, Pages 1903-1912

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585221102587

Keywords

Multiple sclerosis; sodium magnetic resonance imaging; benign; neuronal degeneration; disability

Funding

  1. ARSEP Fondation, Association SEP Pays d'Aix
  2. Novartis France

Ask authors/readers for more resources

The study aimed to compare grey-matter sodium abnormalities (GMSAs) in patients with benign multiple sclerosis (BMS) and non-benign multiple sclerosis (NBMS). The results showed that GMSAs were detected in both BMS and NBMS patients, especially in those with relapsing-remitting and secondary progressive multiple sclerosis. Thalamic volume was independently associated with BMS status, and the absence of GMSAs was independently associated with BMS when excluding patients with significant cognitive alteration.
Objective: Quantification of brain injury in patients with variable disability despite similar disease duration may be relevant to identify the mechanisms underlying disability in multiple sclerosis (MS). We aimed to compare grey-matter sodium abnormalities (GMSAs), a parameter reflecting neuronal and astrocyte dysfunction, in MS patients with benign multiple sclerosis (BMS) and non-benign multiple sclerosis (NBMS). Methods: We identified never-treated BMS patients in our local MS database of 1352 patients. A group with NBMS was identified with same disease duration. All participants underwent Na-23 magnetic resonance imaging (MRI). The existence of GMSA was detected by statistical analysis. Results: In total, 102 individuals were included (21 BMS, 25 NBMS and 56 controls). GMSA was detected in 10 BMS and 19 NBMS (11/16 relapsing-remitting multiple sclerosis (RRMS) and 8/9 secondary progressive multiple sclerosis (SPMS) patients) (p = 0.05). On logistic regression including the presence or absence of GMSA, thalamic volume, cortical grey-matter volume and T2-weighted lesion load, thalamic volume was independently associated with BMS status (odds ratio (OR) = 0.64 for each unit). Nonetheless, the absence of GMSA was independently associated when excluding patients with significant cognitive alteration (n = 7) from the BMS group (OR = 4.6). Conclusion: Detection of GMSA in individuals and thalamic volume are promising to differentiate BMS from NBMS as compared with cortical or whole grey-matter atrophy and T2-weighted lesions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available